Future of Monoclonal Antibody Therapy in Parkinson's Disease.
作者信息
Kharel Sanjeev, Ojha Rajeev
机构信息
Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
Department of Neurology, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal.
出版信息
Ann Neurosci. 2023 Jan;30(1):8-10. doi: 10.1177/09727531221136349. Epub 2022 Nov 17.
Abstract
摘要
相似文献
1
Future of Monoclonal Antibody Therapy in Parkinson's Disease.帕金森病单克隆抗体疗法的未来。
Ann Neurosci. 2023 Jan;30(1):8-10. doi: 10.1177/09727531221136349. Epub 2022 Nov 17.
2
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.抗 α-突触核蛋白抗体 BIIB054 的随机 I 期临床试验。
Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17.
3
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.DJ-1（PARK7）在正常人类中枢神经系统和特发性帕金森病中的表达。
Brain. 2004 Feb;127(Pt 2):420-30. doi: 10.1093/brain/awh054. Epub 2003 Dec 8.
4
Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.特发性快速眼动睡眠行为障碍患者下颌下腺α-突触核蛋白评估：病例对照研究。
Lancet Neurol. 2016 Jun;15(7):708-718. doi: 10.1016/S1474-4422(16)00080-6. Epub 2016 Mar 30.
5
ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.ABBV-0805，一种新型针对可溶性聚集α-突触核蛋白的抗体，可延长帕金森病小鼠模型的寿命并防止α-突触核蛋白病理堆积。
Neurobiol Dis. 2021 Dec;161:105543. doi: 10.1016/j.nbd.2021.105543. Epub 2021 Nov 1.
6
Trial of Cinpanemab in Early Parkinson's Disease.西尼潘单抗治疗早期帕金森病的临床试验。
N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.
7
Trial of Prasinezumab in Early-Stage Parkinson's Disease.普拉克索尼单抗治疗早期帕金森病的试验。
N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867.
8
Immunotherapies for Parkinson's Disease: Progression of Clinical Development.帕金森病的免疫疗法：临床开发进展。
CNS Neurol Disord Drug Targets. 2021;20(9):802-813. doi: 10.2174/1871527320666210526160926.
9
Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).物理治疗和职业治疗与不治疗相比在轻至中度帕金森病中的临床疗效和成本效益：一项大型实用随机对照试验（PD REHAB）
Health Technol Assess. 2016 Aug;20(63):1-96. doi: 10.3310/hta20630.
10
Community aquatic therapy for Parkinson's disease: an international qualitative study.社区水上疗法治疗帕金森病：一项国际定性研究。
Disabil Rehabil. 2022 Aug;44(16):4379-4388. doi: 10.1080/09638288.2021.1906959. Epub 2021 Apr 7.
引用本文的文献
1
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies.用于转铁蛋白受体介导的抗体脑内递送的转化型最小生理药代动力学模型
MAbs. 2025 Dec;17(1):2515414. doi: 10.1080/19420862.2025.2515414. Epub 2025 Jun 26.
2
Biological frameworks for Parkinson's disease: the heterogeneity SAAgged.帕金森病的生物学框架：异质性步履蹒跚。 （注：原英文表述不太常规，翻译可能会稍显生硬，大致意思如此）
J Neurol. 2025 Apr 5;272(4):318. doi: 10.1007/s00415-025-13049-5.
3
Influence of alpha-synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α-synuclein seed amplification assay and FDG-PET.α-突触核蛋白对阿尔茨海默病连续体中葡萄糖代谢的影响：α-突触核蛋白种子扩增试验和氟代脱氧葡萄糖正电子发射断层扫描分析
Alzheimers Dement. 2025 Feb;21(2):e14571. doi: 10.1002/alz.14571.
4
Active Immunotherapy for the Prevention of Alzheimer's and Parkinson's Disease.用于预防阿尔茨海默病和帕金森病的主动免疫疗法。
Vaccines (Basel). 2024 Aug 28;12(9):973. doi: 10.3390/vaccines12090973.
5
Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications.针对NRF2通路进行神经退行性疾病的疾病修饰：机制与治疗意义
Front Pharmacol. 2024 Jul 25;15:1437939. doi: 10.3389/fphar.2024.1437939. eCollection 2024.
6
ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO.具有可编程靶抗原蛋白水解（PTAP）融合的工程化纳米抗体在体外和体内调节细胞内α-突触核蛋白。
Res Sq. 2024 Mar 28:rs.3.rs-4088206. doi: 10.21203/rs.3.rs-4088206/v1.
7
Old problems, new solutions: harnessing technology and innovation in Parkinson's disease-evidence and experiences from Thailand.旧问题，新解决方案：利用技术和创新治疗帕金森病——来自泰国的证据和经验。
J Neural Transm (Vienna). 2024 Jun;131(6):721-738. doi: 10.1007/s00702-023-02727-1. Epub 2024 Jan 8.
本文引用的文献
1
Monoclonal Antibody Therapy in Parkinson's Disease - The End?帕金森病中的单克隆抗体疗法——终结？
N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.
2
Trial of Prasinezumab in Early-Stage Parkinson's Disease.普拉克索尼单抗治疗早期帕金森病的试验。
N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867.
3
Trial of Cinpanemab in Early Parkinson's Disease.西尼潘单抗治疗早期帕金森病的临床试验。
N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.
4
Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.帕金森病临床试验的当前疗法：2021年更新
Pharmaceuticals (Basel). 2021 Jul 25;14(8):717. doi: 10.3390/ph14080717.
5
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.抗 α-突触核蛋白抗体 BIIB054 的随机 I 期临床试验。
Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17.
6
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.PRX002/RG7935（一种抗α-突触核蛋白单克隆抗体）多次递增剂量用于帕金森病患者的安全性和耐受性：一项随机临床试验。
JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487.
7
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.抗α-突触核蛋白免疫疗法可减少轴突中α-突触核蛋白的传播和联合病毒载体及突触核蛋白病转基因模型中的变性。
Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.
8
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.抗体辅助清除细胞外α-突触核蛋白可防止细胞间聚集物的传播。
J Neurosci. 2012 Sep 26;32(39):13454-69. doi: 10.1523/JNEUROSCI.1292-12.2012.
9
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.血清尿酸作为帕金森病临床和影像学进展的预测指标。
Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.
10
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.α-突触核蛋白免疫对帕金森病小鼠模型的影响。
Neuron. 2005 Jun 16;46(6):857-68. doi: 10.1016/j.neuron.2005.05.010.
Zotero 插件